Mesoblast Appoints New Chair to Drive Commercialization Efforts
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Leadership Transition: Mesoblast announces the retirement of Chair Jane Bell, with Philip Facchina appointed as the new Chair, reflecting the company's evolution post-FDA approval towards commercialization, aimed at enhancing governance and strategic execution.
- Board Restructuring: New Chair Facchina brings over 40 years of corporate strategy and finance experience, while Cobley takes on the Audit and Risk Committee chair, ensuring the board possesses diverse expertise to support future growth.
- Strategic Focus: This transition is part of the company's periodic review of board composition and leadership structure, aimed at enhancing commercial delivery capabilities and shareholder value, with plans to strengthen U.S. market expertise in the next twelve months.
- Commitment to Innovation: Mesoblast is dedicated to developing cell therapies for various inflammatory diseases, with Ryoncil® already FDA-approved, marking the company's leadership in cellular medicine and plans to expand its global market presence.
Analyst Views on MESO
Wall Street analysts forecast MESO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MESO is 29.50 USD with a low forecast of 24.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 18.580
Low
24.00
Averages
29.50
High
35.00
Current: 18.580
Low
24.00
Averages
29.50
High
35.00
About MESO
Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
